Premium
Eosinophils as putative therapeutic targets in bullous pemphigoid
Author(s) -
Simon Dagmar,
Borradori Luca,
Simon HansUwe
Publication year - 2017
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.13416
Subject(s) - bullous pemphigoid , autoantibody , chemokine , pathogenesis , immunology , eosinophil , medicine , pemphigoid , infiltration (hvac) , blisters , melanocyte , pathology , antibody , immune system , melanoma , cancer research , physics , asthma , thermodynamics
Bullous pemphigoid ( BP ) is the most common autoimmune subepidermal blistering skin disease and is characterized by the presence of autoantibodies directed against the hemidesmosomal proteins BP 180 and BP 230 that can be detected in the skin and serum of BP patients. Histologically, the dermal infiltration of eosinophils is obvious. The objective of this review was to present evidence that eosinophils play a key role in the pathogenesis of BP . Eosinophils, together with cytokines and chemokines regulating their production, recruitment and activation, are abundantly present in lesional skin, in blisters and in peripheral blood of patients with BP . Recently, using a cryosection model, eosinophils were demonstrated to induce dermal‐epidermal separation in the presence of BP antibodies. Thus, eosinophils and their products, as well as mediators regulating their function, present promising targets for the treatment of BP .